Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Update

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the target of a large increase in short interest in January. As of January 30th, there was short interest totaling 206,238 shares, an increase of 278.5% from the January 15th total of 54,493 shares. Based on an average daily volume of 296,509 shares, the short-interest ratio is presently 0.7 days. Currently, 6.1% of the shares of the company are sold short. Currently, 6.1% of the shares of the company are sold short. Based on an average daily volume of 296,509 shares, the short-interest ratio is presently 0.7 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Capstone Therapeutics stock. World Investment Advisors acquired a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 29,000 shares of the company’s stock, valued at approximately $38,000. World Investment Advisors owned 0.40% of Capstone Therapeutics at the end of the most recent reporting period. 2.55% of the stock is owned by institutional investors.

Capstone Therapeutics Price Performance

NASDAQ:CAPS traded down $0.01 during trading hours on Thursday, hitting $0.51. 20,139 shares of the stock were exchanged, compared to its average volume of 195,968. The company has a current ratio of 0.95, a quick ratio of 0.35 and a debt-to-equity ratio of 0.29. The firm’s fifty day moving average price is $0.71 and its 200 day moving average price is $1.01. The company has a market cap of $4.25 million, a P/E ratio of -0.54 and a beta of -1.21. Capstone Therapeutics has a 52-week low of $0.49 and a 52-week high of $4.18.

Capstone Therapeutics (NASDAQ:CAPS) last announced its quarterly earnings data on Tuesday, November 18th. The company reported ($0.35) EPS for the quarter. The company had revenue of $13.65 million for the quarter. Capstone Therapeutics had a negative return on equity of 29.50% and a negative net margin of 12.40%.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capstone Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.